-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Yitengjiahe (06998.HK) announced that the Phase IB/II clinical trial of the company's highly differentiated and innovative PD-1/CTLA-4/VEGF tri-specific antibody GB268 for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer TNBC and hormone receptor-positive HER2 negative HR/HER2- breast cancer) successfully completed the first patient administration on August 5, 2026.

Zhitongcaijing·08/06/2026 14:33:36
Listen to the news
Zhitong Finance App News, Yitengjiahe (06998.HK) announced that the Phase IB/II clinical trial of the company's highly differentiated and innovative PD-1/CTLA-4/VEGF tri-specific antibody GB268 for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer TNBC and hormone receptor-positive HER2 negative HR/HER2- breast cancer) successfully completed the first patient administration on August 5, 2026.